Analysts Set Expectations for Rezolute FY2025 Earnings

Rezolute, Inc. (NASDAQ:RZLT) – Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for Rezolute in a research note issued on Tuesday, January 21st. Cantor Fitzgerald analyst P. Stavropoulos forecasts that the company will post earnings of ($0.97) per share for the year. The consensus estimate for Rezolute’s current full-year earnings is ($0.99) per share.

Rezolute (NASDAQ:RZLT) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.13.

Several other research firms have also commented on RZLT. Wedbush reissued an “outperform” rating and issued a $112.00 target price on shares of Rezolute in a report on Monday, November 4th. HC Wainwright reiterated a “buy” rating and issued a $14.00 price objective on shares of Rezolute in a report on Friday, November 8th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $24.13.

Rezolute Trading Up 3.7 %

Shares of RZLT opened at $4.99 on Thursday. The firm has a market capitalization of $289.12 million, a price-to-earnings ratio of -3.93 and a beta of 1.08. The firm’s fifty day simple moving average is $4.89 and its 200-day simple moving average is $4.85. Rezolute has a twelve month low of $0.92 and a twelve month high of $6.19.

Insider Activity at Rezolute

In other news, CFO Daron Evans purchased 10,000 shares of the business’s stock in a transaction on Wednesday, December 18th. The shares were bought at an average price of $4.29 per share, with a total value of $42,900.00. Following the completion of the transaction, the chief financial officer now directly owns 150,900 shares in the company, valued at approximately $647,361. This represents a 7.10 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 18.39% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Rezolute

Large investors have recently modified their holdings of the company. Marshall Wace LLP purchased a new stake in Rezolute in the 2nd quarter valued at $4,503,000. Affinity Asset Advisors LLC grew its position in Rezolute by 15.6% during the 2nd quarter. Affinity Asset Advisors LLC now owns 1,850,000 shares of the company’s stock worth $7,955,000 after purchasing an additional 250,000 shares during the last quarter. Geode Capital Management LLC increased its stake in Rezolute by 39.0% in the third quarter. Geode Capital Management LLC now owns 491,601 shares of the company’s stock valued at $2,385,000 after purchasing an additional 137,905 shares during the period. Exome Asset Management LLC raised its holdings in shares of Rezolute by 24.7% in the third quarter. Exome Asset Management LLC now owns 352,056 shares of the company’s stock valued at $1,707,000 after buying an additional 69,656 shares during the last quarter. Finally, Dimensional Fund Advisors LP acquired a new stake in shares of Rezolute during the second quarter worth about $255,000. 82.97% of the stock is owned by institutional investors and hedge funds.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.